Αρχική World News First targeted treatment approved for advanced prostate cancer on NHS in Scotland

First targeted treatment approved for advanced prostate cancer on NHS in Scotland

An image of prostate cancer cells under the microscope.

The Scottish Medicines Consortium (SMC) has approved the use of the drug olaparib for some people in Scotland with a type of advanced prostate cancer.

Olaparib (Lynparza) will be made available on the NHS in Scotland as a treatment for adults with prostate cancer that’s spread to other parts of the body and has stopped responding to treatments or surgery designed to reduce testosterone production (castration resistant).

It will be an option for people with faults in the BRCA1 or BRCA2 genes – changes in particular genes that increase the chance of developing cancer – and where people’s cancers have progressed after being treated with a hormone therapy, such as abiraterone or enzalutamide.

For those advanced prostate cancer patients who can now get olaparib, today’s decision will offer them a treatment option which can give them time to make more memories with their loved ones.

David Ferguson, public affairs manager for Cancer Research UK in Scotland.

A targeted treatment

1 in 400 people in the UK have the BRCA1 or BRCA2 gene mutations, both of which are associated with an increased risk of developing prostate cancer. Patients with BCRA-positive diseases also tend to be of a younger age and experience more aggressive forms of cancer.

Olaparib is a type of targeted cancer treatment that blocks an enzyme called PARP from working, known as a PARP inhibitor. Without PARP, it’s more difficult for cancer cells to repair, making them more likely to die.

“Cancer Research UK played a leading role in the first clinical trials for olaparib, which led to it being used routinely to treat ovarian cancer in patients who have the BRCA1 and BRCA2 gene faults and it’s really encouraging that olaparib can now be used for more types of cancer,” said David Ferguson, Cancer Research UK’s public affairs manager in Scotland.

Clinical trial results find olaparib to be superior

In a late-stage clinical trial, patients taking olaparib lived without their cancer getting any bigger for an average of 7.4 months, in comparison to 3.6 months for those taking existing treatments, in this case either abiraterone or enzalutamide.

In the clinical trial, olaparib was compared with the investigators choice of hormone therapy. However, clinical expert advice is that chemotherapy is likely to be the most relevant comparator in NHS Scotland.

Although there was no direct comparison of olaparib to chemotherapy, an indirect treatment comparison was made for olaparib versus the chemotherapy drug cabazitaxel. The results favoured olaparib over cabazitaxel for length of time before the cancer progressed, although the difference in overall survival was uncertain.

The SMC also considered patient and clinician views, including the hope that olaparib would improve people with advanced prostate cancer’s quality of life by giving people more time before their cancer grows.

The group also said that an oral treatment would allow patients to receive treatment at home rather than the hospital visits currently required for chemotherapy. Olaparib also has more tolerable side effects than chemotherapy.

“It’s great news that olaparib has been approved to treat metastatic prostate cancer for people in Scotland who carry BRCA1 and BRCA2 gene mutations,” said Ferguson. “Olaparib is a really important tool for treating patients with these mutations who have cancer which has come back after chemotherapy.”

England, Wales and Northern Ireland have a separate process for reviewing drugs.

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...